UMIN-ICDS Clinical Trial

Unique ID issued by UMIN UMIN000049837
Receipt number R000056766
Scientific Title A Randomized Controlled Trial for the Effectiveness of Belt Electrode Skeletal Muscle Electrical Stimulation (B-SES) Trailing
Date of disclosure of the study information 2022/12/20
Last modified on 2023/08/24 12:56:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A Randomized Controlled Trial for the Effectiveness of Belt Electrode Skeletal Muscle Electrical Stimulation (B-SES) Trailing

Acronym

A Randomized Controlled Trial for the Effectiveness of Belt Electrode Skeletal Muscle Electrical Stimulation (B-SES) Trailing (RCT-BSES)

Scientific Title

A Randomized Controlled Trial for the Effectiveness of Belt Electrode Skeletal Muscle Electrical Stimulation (B-SES) Trailing

Scientific Title:Acronym

A Randomized Controlled Trial for the Effectiveness of Belt Electrode Skeletal Muscle Electrical Stimulation (B-SES) Trailing (RCT-BSES)

Region

Japan


Condition

Condition

frail older adults

Classification by specialty

Geriatrics Orthopedics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate the effects of B-SES training on improving physical and cognitive functions, and to search for biomarkers containing blood that reflects these effects

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Short Physical Performance Battery (SPPB)

Key secondary outcomes

At enrollment and after 12 weeks of intervention:
Blood examination (complete blood count, biochemistry), gait speed, knee extension muscle strength, grip strength, Trail Making Test, Stroop Test, Japanese version of the Montreal Cognitive Assessment (MoCA-J), aging-related factors (GDF-15, FGF-21, Apelin, Progranulin, TNF-alpha, CXCL9, CXCL10, NAMPT, BDNF, Adiponectin, IGF-1, DHEA-S, etc), metabolome, transcriptome, adverse events, etc.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

Belt electrode skeletal muscle electrical stimulation (B-SES) training

Interventions/Control_2

The Home Exercise Program for Older People (HEPOP)

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Among older people aged 65 years old and over, who agreed to register for "Registry Study of Locomo-Frailty-Sarcopenia", those who met all of the following criteria
1) The Japanese version of the Cardiovascular Health Study >/= 2
2) 6-9 of the SPPB score
3) MMSE >/= 24 and MoCA-J <26

Key exclusion criteria

If persons meet even one of the following criteria, they cannot participate in this study.
1) Those who indicated their intention to refuse to participate in the study
2) Persons who are judged inappropriate for inclusion in the research by the principal investigator and co-investigator
3) Persons with certification of long-term care need (long-term care level 1 or higher)
4) Decrease in ADL (Katz Index: less than 5 points)
5) Persons with hearing loss or visual impairment that interferes with daily life
6) Persons diagnosed with the following diseases: quadriplegia, major depression, dementia, intractable neurological diseases (Parkinson's disease and related diseases, amyotrophic lateral sclerosis, degenerative diseases, etc.)
7) Subjects receiving treatment with steroid drugs
8) Subjects who are undergoing treatment for malignant tumors
9) Subjects who are contraindicated for the implementation of B-SES training

Target sample size

40


Research contact person

Name of lead principal investigator

1st name Shosuke
Middle name
Last name Satake

Organization

National Center for Geriatrics and Gerontology

Division name

Department of Geriatric Medicine

Zip code

474-8511

Address

7-430 Morioka-cho, Obu City, Aichi Prefecture

TEL

0562-46-2311

Email

satakes@ncgg.go.jp


Public contact

Name of contact person

1st name Shosuke
Middle name
Last name Satake

Organization

National Center for Geriatrics and Gerontology

Division name

Department of Geriatric Medicine

Zip code

474-8511

Address

7-430 Morioka-cho, Obu City, Aichi Prefecture

TEL

0562-46-2311

Homepage URL


Email

satakes@ncgg.go.jp


Sponsor or person

Institute

National Center for Geriatrics and Gerontology

Institute

Department

Personal name



Funding Source

Organization

Japan Agency for Medical Research and Development

Organization

Division

Category of Funding Organization

Government offices of other countries

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

National Center for Geriatrics and Gerontology

Address

7-430 Morioka-cho, Obu City, Aichi Prefecture, 474-8511, Japan

Tel

0562-46-2311

Email

yaday@ncgg.go.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

国立長寿医療研究センター(愛知県)


Other administrative information

Date of disclosure of the study information

2022 Year 12 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2022 Year 10 Month 24 Day

Date of IRB

2022 Year 10 Month 24 Day

Anticipated trial start date

2023 Year 01 Month 12 Day

Last follow-up date

2025 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2022 Year 12 Month 20 Day

Last modified on

2023 Year 08 Month 24 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000056766


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name